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Abstract (Word count 250 – current 248)  
We sought to identify fibroblast growth factor receptor 2 (FGFR2) kinase domain 
mutations that confer resistance to the pan-FGFR inhibitor, dovitinib, and explore the 
mechanism of action of the drug-resistant mutations. We cultured BaF3 cells 
overexpressing FGFR2 in high concentrations of dovitinib and identified fourteen 
dovitinib-resistant mutations, including the N550K mutation observed in 25% of 
FGFR2mutant endometrial cancers (EC). Structural and biochemical in vitro kinase 
analyses, together with BaF3 proliferation assays, showed that the resistance 
mutations elevate the intrinsic kinase activity of FGFR2. BaF3 lines were used to 
assess the ability of each mutation to confer cross-resistance to PD173074 and 
ponatinib. Unlike PD173074, ponatinib effectively inhibited all the dovitinib-resistant 
FGFR2 mutants except the V565I gatekeeper mutation, suggesting ponatinib but not 
dovitinib targets the active conformation of FGFR2 kinase. EC cell lines expressing 
wild-type FGFR2 were relatively resistant to all inhibitors. Whereas EC cell lines 
expressing mutated FGFR2 showed differential sensitivity. Within the FGFR2mutant 
cell lines, 3/7 showed marked resistance to PD173074 and relative resistance to 
dovitinib and ponatinib. This suggests that alternative mechanisms distinct from 
kinase domain mutations are responsible for intrinsic resistance in these three EC 
lines. Finally, overexpression of FGFR2N550K in JHUEM-2 cells (FGFR2C383R) 
conferred resistance (~5 fold) to PD173074, providing independent data that 
FGFR2N550K can be associated with drug resistance. Biochemical in vitro kinase 
analyses also shows ponatinib is more effective than dovitinib at inhibiting 
FGFR2N550K. We propose tumors harboring mutationally activated FGFRs should be 
treated with FGFR inhibitors that specifically bind the active kinase. 
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Introduction (Word count 5034 without methods) 
 
Constitutive fibroblast growth factor receptor (FGFR) signaling due to FGFR 
amplifications, chromosomal translocations or gain-of-function mutations contributes 
to the development and progression of multiple cancers (reviewed in (1-3)). Tumor 
types associated with genetic aberrations in the FGF/FGFR family include lung and 
breast cancer (FGFR1), gastric cancer and endometrial cancer (FGFR2), bladder 
cancer and multiple myeloma (FGFR3), and rhabdomyosarcoma (FGFR4). 
Preclinical in vitro and in vivo studies have indicated that FGFR kinase inhibition in 
FGFR dependent tumors is a rational approach to target these cancers. While more 
selective anti-FGFR inhibitors are entering early clinical development, the most 
clinically advanced inhibitors are multi-kinase inhibitors, often developed as anti-
angiogenic agents. Dovitinib is the multi-kinase inhibitor that has shown the most 
promising results in multiple FGFR-dependent cancers.  
Dovitinib (TKI258, previously CHIR258) is an ATP-competitive tyrosine kinase 
inhibitor with activity against FGFR1-4, VEGFR1-3, PDGFRB, c-KIT, CSF1R and 
FLT3 (4). It has shown preclinical anti-tumor activity in a range of different cancers 
(5-8) including cancer models characterized by FGFR activation such as multiple 
myeloma, acute myelogenous leukemia, prostate, bladder and gastric cancer (4, 9-
14). Dovitinib has demonstrated anti-tumor activity in several phase I clinical trials 
with partial responses (PRs) and stable disease (SD) observed in several patients 
(15). Dovitinib is currently in phase II clinical trials in renal cell carcinoma patients as 
an anti-angiogenic agent as well as in several malignancies associated with FGFR 
activation e.g. multiple myeloma with t(4;14) translocation (activated FGFR3) 
(Clinical Trials identifier: NCT01058434), and advanced urothelial carcinomas with 
and without mutations in FGFR3 (NCT00790426). It is also in a clinical phase II 
study in patients with advanced endometrial cancers expressing wild-type or mutant 
FGFR2 (NCT01379534).  
Despite the initial clinical effectiveness of kinase inhibitors, the long-term 
efficacy of these agents is hampered by intrinsic resistance in a subset of patients 
and the development of acquired resistance in a proportion of responders. One 
resistance mechanism common to many kinase inhibitors is the acquisition of 
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secondary mutations in the kinase domain.  Mutations of the gatekeeper residue of 
the target kinase are the most frequently detected drug resistant mutation in the 
clinic. Notably, mutation of the gatekeeper residue in Bcr-Abl (T315I) is detected with 
high frequency in chronic myelogenous leukemia (CML) patients with resistance 
against imatinib (17, 18). Likewise, mutation of the gatekeeper residue (T790M) in 
the epidermal growth factor receptor (EGFR) occurs in ~50% of tumors with acquired 
erlotinib or gefitinib resistance and represents a major obstacle for treatment 
success with targeted EGFR inhibitors (19-21). Substitutions of gatekeeper residues 
with larger hydrophobic residues have been shown to sterically interfere with access 
of drug to the hydrophobic pocket in the ATP binding cleft. Bcr-Abl inhibitors have 
also been shown to form critical hydrogen bonds with the side chain hydroxyl group 
of T315 (22). Moreover, the gatekeeper mutations appear to enhance tyrosine 
kinase activity by stabilizing a hydrophobic spine, a network of hydrophobic 
interactions characteristic of activated kinases (23). In CML, the realization that 
patients acquire resistance after initial response led to the development of more 
potent second generation inhibitors such as nilotinib and dasatinib (24); however like 
imatinib, these inhibitors do not have activity against the T315I gatekeeper mutation. 
This led to the structure-based design of ponatinib (AP24534), a third generation 
inhibitor designed to have activity against wild-type Bcr-Abl as well as Bcr-Abl-T315I.  
Despite the importance of FGFRs as cancer drug targets, little is known about 
the repertoire of mutations in FGFRs that confer resistance to current FGFR 
inhibitors. Mutations of the gatekeeper residues in FGFR1 (V561M) and FGFR3 
(V555M) have been shown to result in in vitro resistance to the multi-kinase inhibitor 
PP58 and the FGFR inhibitor AZ12908010 respectively (25). Thus indicating that 
mutation of the gatekeeper residue may be a general mechanism of resistance to 
receptor tyrosine kinase (RTK) inhibitors.  
 The BaF3 screening strategy developed by von Bubnoff et al. is considered 
the “gold standard” method to identify drug-resistant mutations in a variety of RTKs 
and non-receptor kinases (26, 27). In this method, BaF3 cells are made dependent 
on the desired RTK, cultured in the presence of an inhibitor against that RTK, and 
resistant colonies that emerge are screened for drug resistant mutations. This 
approach has been successfully used to identify tyrosine kinase inhibitor (TKI)-
resistant mutations in Bcr-Abl, FLT3, PDGFRA, MET, EGFR and JAK2 (28-33) and 
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has effectively reproduced the pattern and relative abundance of Bcr-Abl mutations 
seen clinically in imatinib-resistant patients (28).  In this study, we used the BaF3 
screening strategy to identify FGFR2 mutations that impart resistance to dovitinib 
and examined the effect of these mutations on FGFR2 kinase activity in vitro and in 
stable FGFR2 expressing BaF3 cells. We show that the dovitinib resistant FGFR2 
mutations act by stabilizing the active conformation of the kinase.  We also examined 
the ability of these dovitinib-resistant mutations to confer cross-resistance to other 
FGFR inhibitors including PD173074 and ponatinib. Importantly we discovered that 
ponatinib is capable of inhibiting dovitinib-resistant gain-of-function mutations 
indicating that ponatinib may be more effective as a first line therapy as well as in the 
second line setting to target tumors with resistance to dovitinib. Treatment of a panel 
of FGFR2 mutant endometrial cancer cell lines with dovitinib and ponatinib revealed 
different levels of drug sensitivity within cell lines expressing the same FGFR2 
mutation, suggesting other intrinsic mechanisms of resistance may also be present 
in patient tumors.   
Results 
BaF3 screen for dovitinib-resistant FGFR2 mutations 
BaF3 cells stably expressing the ‘b’ splice isoform of FGFR2 (FGFR2b, 
NM_022970) were treated with 100, 200, and 300 nM dovitinib corresponding to 
concentrations that are 5, 10, and 15 times the IC50 value of dovitinib in this cell line. 
In the presence of 100 nM dovitinib, 73 of 384 wells grew out, corresponding to a 
resistant clone frequency of 0.76 per million cells. 19 of 384 wells and 9 of 384 wells 
grew out in the 200 nM and 300 nM dovitinib-treated groups, respectively, resulting 
in a resistant clone frequency of 0.20 and 0.09 per million cells. Sequencing of the 
intracellular domain of FGFR2 from 63 of the dovitinib-resistant BaF3.FGFR2 clones 
led to the identification of mutations in 26 resistant clones (41%). The mutation 
frequency increased with dovitinib concentration, with 7/35 (20%), 13/19 (68%), and 
6/9 (67%) of resistant clones containing a FGFR2 mutation for clones selected at 
100, 200, and 300 nM, respectively (Supplemental Table 1).  
Eleven different FGFR2 mutations, affecting nine amino acids, were detected 
(Figure 1A).  Ten mutations map into the kinase domain (M536I, M538I, I548V, 
N550H/K/S, V565I, E566G, L618M, and E719G) whereas the Y770fsX14 localizes to 
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the C-terminal tail past the kinase domain (Figure 1A).  The most commonly mutated 
codon was N550, with mutations accounting for 73% (19 out of 26) of FGFR2 
mutations. One resistant clone harboured two mutations, N550H and E719G.  
Mutation at the gatekeeper residue (V565I) was identified in one clone.  
We also performed parallel dovitinib resistance screens using BaF3 cells 
expressing either of the FGFR2 activating mutations, S252W or N550K. The S252W 
mutation is the most common FGFR2 mutation seen in endometrial tumors and 
maps to the extracellular ligand-binding region of FGFR2. Structural and biochemical 
studies have shown that this mutation results in ligand-dependent receptor activation 
by introducing additional contacts between FGFR and FGF ligand (34), and as such 
we did not expect a different pattern of resistance mutations. N550K is the second 
most common FGFR2 mutation identified in endometrioid endometrial cancer (35) 
and we show herein that this mutation activates the kinase. BaF3 cells expressing 
S252W mutant FGFR2 show similar dovitinib sensitivity to BaF3 cells expressing 
wild-type FGFR2 (Supplemental Figure 1) and were thus treated in a similar manner 
with 100, 200, or 300 nM dovitinib.  Resistant clones grew out in 51/384 wells and 
the FGFR2 kinase domain was sequenced in thirty-five resistant clones that grew out 
at the two highest dovitinib concentrations. FGFR2 mutations were identified in four 
clones affecting three amino acids: N550T, E566A (two independent clones), and 
K642N. Although we observed a reduced mutation rate in the resistant BaF3.FGFR2 
S252W BaF3 clones, the presence of the S252W mutation did not dramatically alter 
the spectrum of dovitinib-resistant mutations identified as two of these codons 
(N550, E566) were also mutated in the wild-type FGFR2 BaF3 screen. Moreover, all 
three mutations were confirmed to confer resistance to dovitinib when expressed in 
conjunction with the activating S252W mutation in proliferation assays 
(Supplemental Figure 1). For the N550K resistance screen, BaF3 cells expressing 
N550K mutant FGFR2 were treated with 2 µM, 4 µM, or 6 µM dovitinib, 
corresponding to 5, 10, and 15-times the IC50, because, as noted above, N550K 
already imparts significant resistance to dovitinib in isolation. No resistant clones 
were isolated after dovitinib treatment in the N550K resistance screen. 
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Reintroduction of the mutations confirmed the identified mutations induce 
dovitinib resistance. 
To confirm that the mutations identified in the BaF3 screen were sufficient to 
confer dovitinib-resistance, independent BaF3 cell lines stably expressing FGFR2 
harboring the putative drug-resistant mutations identified in the initial BaF3 screen 
were generated (Figure 1B). As the Y770fsX14 C-terminal deletion mapped away 
from the ATP-binding site and could not be identified with the C-terminal antibody we 
used, this mutation was not assessed. The sensitivity of these stable cell lines to 
dovitinib was then measured by assessing cell viability at increasing dovitinib 
concentrations (Figure 1C).  As the activating N550K mutation was identified in the 
resistance screen, we also assessed the sensitivity of the other major activating 
mutation seen in patients, K660E. All mutations with the exception of E719G led to 
drug resistance as manifested by 2.11 to 15.04-fold increases in IC50 value.  The 
N550K, V565I, K660E and E566G mutations imparted the greatest magnitude of 
resistance (Figure 1C). Dovitinib sensitivity of BaF3 cells expressing the E719G 
mutant FGFR2 was not significantly different than of those expressing wild-type 
FGFR2. The clone where the E719G mutation was identified also harbored an 
N550H mutation in FGFR2, so presumably the latter N550H mutation conveyed 
resistance in this clone and the E719G mutation represents a passenger mutation. 
Dovitinib-resistant mutations at N550 and E566 disrupt the molecular brake to 
activate the FGFR2 kinase. 
 To understand the molecular mechanisms by which these mutations confer 
resistance to dovitinib, a structural model of FGFR2 kinase bound to dovitinib was 
created by superimposing the structure of the A-loop phosphorylated activated wild-
type FGFR2 kinase domain (PDB ID: 2PVF) (36) onto the structure of the CHK-1 
kinase domain in complex with the inhibitor 4-(Aminoalkylamino)-3-benzimidazole-
quinolinones complex structure (PDB ID: 2GDO) (37). Structural analysis shows that 
the V565I gatekeeper mutation could confer drug resistance by sterically hindering 
access of the drug into the hydrophobic rear corner of the ATP binding cleft of the 
kinase (Figure 2A, B).  In contrast, the remaining mutations are unlikely to cause 
drug resistance by sterically interfering with drug binding.  Instead these mutations 
appear to impart drug resistance by stabilizing the active conformation of the FGFR2 
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kinase.  Specifically, several of the dovitinib-resistant mutations identified in the 
original and FGFR2 S252W screen (N550H/K/S/T, E566G/A, K642N) target the triad 
of residues (N550, E566 and K642) that form an autoinhibitory network of hydrogen 
bonds, termed the molecular brake, at the kinase hinge region.  This molecular brake 
restricts the motion of the kinase into the active state (36). Mutation of these 
residues have been shown to disengage this brake, permitting the kinase to more 
readily adopt the active conformation (Figure 2C, D) (36). These data suggest that 
the N550H/K/S/T, E566G/A, and K642N dovitinib-resistant mutations favor the active 
conformation of the kinase (Figure 2E, F), implying that dovitinib does not act on the 
active kinase conformation.  
Several of the dovitinib-resistant mutations namely M536I, M538I, I548V, and 
L618M appear to stabilize the active kinase conformation by strengthening the 
hydrophobic spine of the FGFR2 kinase (Figure 2G). Furthermore, the gatekeeper 
residue is positioned at the top corner of the hydrophobic spine and its mutation to 
bulkier hydrophobic residues has been also proposed to activate the kinase through 
fortifying the hydrophobic spine. Together, these data suggest that dovitinib-resistant 
mutations act by stabilizing the active kinase conformation either through 
disengaging the molecular brake or strengthening the hydrophobic spine.  The V565I 
gatekeeper mutation can additionally confer drug resistance through steric 
hindrance. 
Dovitinib-resistant mutations elevate the intrinsic kinase activity of FGFR2 
 To test our structural prediction that the dovitinib-resistant mutations confer 
resistance by stabilizing the active conformation of the kinase we decided to study 
the effect of the drug-resistant mutations on the intrinsic kinase activity of FGFR2 
kinase.  Recombinant wild-type and mutated kinase domain harboring the drug-
resistant mutations were expressed and purified to homogeneity and their substrate 
phosphorylation activities were compared using native-PAGE coupled with time-
resolved mass spectrometry. Briefly, wild-type or drug-resistant mutant FGFR2 
kinases were incubated with peptide substrate in the presence of ATP and MgCl2. 
The C-terminal tail of the FGFR2 kinase, which contains five authentic 
phosphorylation sites, served as the substrate. Phosphorylation reactions were 
quenched at different time points with the addition of EDTA. The formation of 
phosphorylated species was monitored by native-PAGE and analyzed by mass 
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spectrometry and the percentage of at least one site phosphorylation on the 
substrate was quantitated using the peak intensity data generated by mass 
spectrometry (Figure 3A, Supplemental Figure 2). Compared to wild-type kinase, the 
drug-resistant mutant FGFR2 kinases exhibited increased ability to phosphorylate 
the substrate, demonstrating that the dovitinib-resistant mutations elevate the 
intrinsic activity of the enzyme.  
Dovitinib-resistant mutations result in ligand-dependent receptor activation in 
vitro  
To validate our in vitro data we next tested the ability of the drug-resistant 
mutations to elevate the kinase activity of full-length receptor by measuring ligand–
independent and dependent proliferation of the BaF3 cell lines expressing the drug-
resistant FGFR2b mutants. None of the dovitinib-resistant mutations was sufficient to 
significantly drive FGF-independent cell survival and proliferation (Supplemental 
Figure 3A). These data may seem conflicting with the in vitro data showing these 
mutations have constitutive activity, however comparative data suggest that FGFR2 
is not able to drive IL3-independent BaF3 proliferation in the same way as FGFR1, 
perhaps reflecting its reduced overall kinase activity. Specifically, BaF3 cells 
expressing FGFR1c N546K demonstrate significant proliferation compared to wild-
type in the absence of ligand in contrast to the homologous N550K mutation in 
FGFR2c that does not (Supplemental Figure 3B).  Nevertheless, in the presence of 
FGF10 (a well-known cognate ligand of FGFR2b) BaF3 cell lines expressing each of 
the dovitinib-resistant mutants displayed increased proliferation compared to cells 
expressing wild-type FGFR2 (Figure 3B) supporting the in vitro findings that the 
dovitinib-resistant mutations increase the tyrosine kinase activity of full-length 
FGFR2b.  
To further corroborate our findings, cell lines expressing drug-resistant 
FGFR2b mutants were incubated with heparan sulphate and FGF10 for 7.5 minutes, 
and the receptor phosphorylation was assessed by Western blot analysis using a 
phospho-FGFR antibody. Densitometric analysis of biological replicate experiments 
shows that the drug-resistant FGFR2 mutants exhibited a 5 to 6-fold increase in 
autophosphorylation as compared to the wild-type FGFR2 (Figure 3C). No increase 
in BaF3 proliferation or receptor phosphorylation in response to FGF10 was seen in 
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the BaF3 cells transduced with FGFR2 K660E, although this mutated receptor 
shows strong constitutive activity in the absence of ligand (Supplemental Figure 3B). 
This is consistent with mislocalization of this activating mutant to the ER/Golgi, 
similar to what has been reported previously for the K650E mutation in FGFR3 (38, 
39). Taken together with the in vitro kinase assay data, these cell-based data 
demonstrate that the dovitinib-resistant mutations increase the tyrosine kinase 
activity of FGFR2. 
Mutations cause cross-resistance to PD173074 but not to ponatinib 
 To examine whether the identified dovitinib-resistant FGFR2 mutations can 
also confer resistance to other FGFR inhibitors, ligand-induced proliferation of BaF3 
cells expressing the drug-resistant FGFR2 was measured in the presence of 
PD173074 and ponatinib. As shown in Figure 4A, the dovitinib-resistant mutations 
also imparted resistance to PD173074. As with dovitinib, the N550K molecular brake 
region mutation and the V565I gatekeeper mutation also caused greatest resistance 
towards PD173074. Interestingly, the N550K mutation provided considerably more 
resistance than N550H and N550S, perhaps indicating that the conformation of 
N550K provides resistance through another mechanism, in addition to loss of the 
molecular brake. In contrast, ponatinib effectively inhibited all the dovitinib-resistant 
FGFR2 mutants with the exception of the V565I gatekeeper mutant (Figure 4B). 
 To further explore the differential sensitivity of ponatinib to the dovitinib-
resistant mutations, BaF3 cell lines expressing wild-type FGFR2b or N550K and 
V565I drug-resistant FGFR2b mutants were incubated with dovitinib or ponatinib 
followed by FGF10 ligand stimulation and the phosphorylation of FGFR2 was 
examined. Treatment with dovitinib reduced receptor phosphorylation in 
BaF3.FGFR2 wild-type cells to ~50% at a concentration of 52.1 nM (Figure 5A, B). In 
contrast, the concentration of dovitinib required to reduce receptor phosphorylation 
to ~50% in BaF3.FGFR2 N550K and BaF3.FGFR2 V565I cells, was 794 nM and 954 
nM, respectively. Ponatinib inhibited phosphorylation of wild-type FGFR2b with an 
IC50 of 30.73 nM that is comparable to that of dovitinib. In stark contrast to dovitinib, 
ponatinib was highly effective in inhibiting the N550K FGFR2 mutant (IC50 of 5.72 
nM), demonstrating the sensitivity of this FGFR2 mutant to ponatinib. Notably, the 
V565I gatekeeper mutant was still refractory to inhibition by ponatinib (IC50 661 nM), 
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emphasizing the potency of this mutation to confer resistance to all three FGFR 
inhibitors. 
Endometrial Cancer Cell Lines expressing various FGFR2 mutations (N550K, 
S252W and C383R) demonstrate both sensitivity and intrinsic resistance to 
FGFR inhibition 
Our lab and others have reported that the AN3CA and MFE296 cell lines, 
which carry the N550K FGFR2 mutation, are sensitive to FGFR inhibition with 
PD174074 (40, 41). To better gauge the relevance of the N550K mutation in 
resistance to FGFR inhibition in the correct cellular context, we identified four 
additional cell lines with mutations in FGFR2 (personal communication, Gordon 
Mills). We hypothesized that a comparison of the mutant FGFR2 cell lines would 
show that all cell lines would be equally sensitive to ponatinib but that the N550K 
lines could show relative resistance to PD173074 and dovitinib (compared to cell 
lines carrying S252W and C383R FGFR2 mutations).  
Sensitivity across the panel was in the order ponatinib (most sensitive), then 
dovitinib, then PD173074 (least sensitive). Ponatinib was more potent than the other 
FGFR inhibitors in both the FGFR2 mutant and FGFR2 wild-type cell lines (e.g. 
Ishikawa) suggesting its increased potency was not only due to its ability to bind the 
active FGFR2 but also due to its multi-kinase nature. We should note that the IC50 
values we report are higher than those that we and others have reported previously 
for several cell lines. However in this report we directly measured cell proliferation 
with a nucleic acid based kit rather than a metabolic based assay (40, 42), or one 
based on cellular protein content (41). Within the FGFR2mutant cell lines, 3/7 showed 
marked resistance to PD173074 (IC50 > 4 µM) including EI, EJ and EN1078D. With 
the exception of EN1078D treated with dovitinib, these three FGFR2mutant cell lines 
also showed relative resistance to dovitinib and ponatinib when compared to the 
average IC50 of the three most sensitive cell lines versus that of the three FGFR2wild-
type cell lines (Table 1). As the same cell lines showed similar relative resistance to 
PD173074, dovitinib and ponatinib it suggests these cell lines have intrinsic 
resistance to FGFR inhibition that is not overcome by an inhibitor that is capable of 
binding to the active conformation of the kinase.    
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Stable expression of N550K mutant FGFR2 in inhibitor sensitive JHUEM-2 cells 
confers resistance to PD173074. 
As those endometrial cancer cell lines carrying the N550K mutation had a 
diverse response to FGFR inhibition (presumably reflecting the acquisition of 
additional genetic/epigenetic changes), we sought an alternative approach to confirm 
whether FGFR2N550K is a true resistance mutation. We stably transfected the 
sensitive JHUEM-2 cell line (FGFR2C383R) with FGFR2N550K. JHUEM-2 cells stably 
expressing an empty vector control, wild-type FGFR2 and an extracellular domain 
activating FGFR2 mutant (Y376C) were also created. We then measured the cell 
viability of these lines in response to FGFR inhibition with dovitinib, PD173074 and 
ponatinib. Although expression of FGFR2N550K did not affect the sensitivity of 
JHUEM-2 cells to dovitinib and ponatinib, it did however cause a ~5 fold increase in 
the IC50 to PD173074 (Figure 7A). As demonstrated in Figure 7B, all three wild-type 
and mutant FGFR2 transfected cell lines express higher levels of FGFR2 than the 
empty vector control line. Indeed the FGFR2N550K expressing cells expressed less 
FGFR2 than the FGFR2Y376C cell line, and yet only the FGFR2N550K cells showed 
increased resistance to PD173074. While N550K did not confer resistance to 
dovitinib and ponatinib when expressed at low levels in JHUEM cells, we were able 
to confirm that N550H imparts resistance to dovitinib using in vitro kinase assays 
(Figure 7C). Similar to the N550H/K-expressing BaF3 cells, in vitro kinase assays 
showed that N550H was more sensitive to ponatinib than dovitinib. Specifically 
dovitinib and ponatinib could inhibit the kinase activity of WT FGFR2 when mixed at 
a kinase:inhibitor molar ratio of 1:2. Ponatinib could inhibit N550H at a similar molar 
ratio whereas dovitinib could not provide the same inhibition even at a molar ratio of 
1:10. The kinase activity of the V565I mutant was resistant to both dovitinib and 
ponatinib even when mixed at a molar ratio of 1:10. These results confirm the BaF3 
data showing that ponatinib is more effective than dovitinib at inhibiting FGFR2N550K 
and that the V565I gatekeeper mutant is resistant to both dovitinib and ponatinib. 
Taken together this confirms our BaF3 data that FGFR2N550K is indeed a true 
resistance mutation. 
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Discussion 
This study provides the first discovery of TKI-resistant mutations in FGFR2, 
an important drug target in endometrial cancer.  These mutations include M536I, 
M538I, I548V, N550H/K/S/T, V565I, E566G/A, L618M and K642N. Given the 
identification of N550K, we also investigated the clinically relevant activating 
mutation, K660E and showed it was associated with resistance to dovitinib and 
PD173074. Identification of the V565I mutation in our screen reiterates mutation of 
the gatekeeper residue as a general mechanism of acquired resistance to TKIs. 
Importantly our structural and biochemical data show that these mutations stabilize 
the active conformation of FGFR2 kinase manifesting in increased intrinsic activity of 
the drug-resistant FGFR2K mutants. Although several resistance mutations were not 
functionally tested (N550T, E566A, K642N), data from the remaining mutations 
indicate that seven of the identified resistance mutations, namely N550H/K/S/T, 
E566G/A and K642N drive the enzyme into the active state by disengaging the 
autoinhibitory molecular brake at the kinase hinge region. The remaining five 
mutations, namely M536I, M538I, I548V, V565I and L618M, stabilize the kinase 
active conformation by strengthening the hydrophobic spine, a network of 
hydrophobic packing interactions between the N- and C-lobe of the kinase that 
characterizes the active conformation of the kinase. It has been suggested that 
dovitinib may inhibit both the active and inactive forms of VEGFR (4). However, our 
findings indicate that dovitinib and PD173074 preferentially bind the inactive form of 
the FGFR2 kinase. In contrast, ponatinib effectively inhibited all of the FGFR2 
activating mutations except the V565I gatekeeper mutation, suggesting that 
ponatinib is capable of targeting both the inactive and the active conformations of the 
kinase. Modeling studies suggest that the gatekeeper mutation, in addition to 
strengthening the hydrophobic spine, may also create a steric conflict for drug 
binding, explaining the exceptional resistance of this mutation to ponatinib (Figure 6).  
 Amino acids corresponding to all the dovitinib-resistant mutations identified in 
FGFR2 are conserved among the other three members of the FGFR family. 
Therefore it is likely that the corresponding mutations in other FGFR family members 
could impart dovitinib-resistance in tumors that are dependent on these FGFRs. All 
three constituents of the molecular brake (N550, E566 and K642) and several 
residues of the hydrophobic spine in FGFR2b are also conserved in VEGFR1, 
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VEGFR2, PDGFRA, PDGFRB, c-KIT and FLT3. Indeed, mutations at the 
homologous residue to FGFR2 (N550) in FLT3 (N676) have been linked to 
resistance to the kinase inhibitor PKC412, including clinical resistance in a patient 
with acute myeloid leukemia (AML) (29, 43). Conversely, N659 in PDGFRA 
(homologous to N550 in FGFR2) is mutated in a subset of GIST tumors but this 
mutation does not result in imatinib resistance in vitro (44).  
In addition to being the most commonly mutated codon identified in our 
resistance screen, N550 is also the second most common amino acid of FGFR2 
altered in endometrioid endometrial cancer (35, 45). As such, cancer patients 
carrying activating mutations at N550 may be resistant to the anti-FGFR activity of 
dovitinib, whereas patients harboring FGFR2 mutations outside the kinase domain 
would be expected to achieve more clinically significant responses. Preliminary 
findings from a phase I/II pharmacodynamic study indicate that oral administration of 
dovitinib at 400 mg/day results in plasma Cmax drug levels of 119 – 382 ng/mL (247 – 
792 nM) (15). With a half-life of approximately 12 hours, dovitinib plasma Cmin levels 
would be expected to be approximately 25% those of the Cmax levels (in the order of 
62 – 198 nM). Based on our in vitro data, effective inhibition of N550K, E566G, 
K660E and V565I would not be expected with these plasma concentrations. Thus we 
propose that patients presenting with N550 and K660 mutations potentially be 
treated with higher doses of dovitinib and for their plasma concentrations to be 
analyzed and correlated with clinical response. It should be noted, however, that 
dovitinib should still exert anti-angiogenic activity in patients with the N550K mutation 
owing to its additional inhibition of VEGFR and PDGFR (15). That being said, we 
would predict fewer partial and complete responses in patients carrying kinase 
domain mutations due to its reduced anti-tumor efficacy. All mutations except V565I 
(which may possibly arise in the context of ponatinib selective pressure) are 
effectively inhibited at achievable plasma levels of ponatinib and as such a multi-
institutional phase II trial of ponatinib in FGFR2 mutation-positive endometrial cancer 
patients is currently in development.   
 The prevalence of drug-resistant mutations affecting N550 was somewhat 
surprising, considering the fact that we, and others, have previously shown that 
endometrial cancer cell lines with FGFR2b N550K mutation are sensitive to 
PD173074 (40, 41). This inconsistency is an important one as our BaF3 resistance 
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screen results may not be readily translated into the clinic in endometrial cancer 
patients treated with dovitinib. To better gauge the relevance of the N550K 
resistance mutation in endometrial cancer cell lines, we ran all three FGFR inhibitors 
in this study across a number of N550K-mutant, non-N550K-mutant and FGFR2 
wild-type cell lines. While we confirmed the JHUEM-2 cell line as an additional 
sensitive cell line, the EJ, EI and to a lesser extent the EN1078D cell line showed 
resistance to the panel of kinase inhibitors. Of these EJ and EN1078D carried an 
N550K mutation and EI carried a S252W mutation. Previous data indicate that the 
MFE319 cell line carrying a S252W mutation is also resistant to FGFR inhibition (47). 
Therefore, only 4/8 (50%) of the endometrial cancer cell lines with known activating 
mutations show sensitivity to FGFR inhibition, contrasting with our original findings 
where 2/2 cell lines showed sensitivity. As sensitivity/resistance does not correlate 
with any specific mutation, sensitivity to FGFR inhibition appears to be more complex 
than simply what FGFR2 mutation is present.  Perhaps intuitively, sensitivity is 
greater for those FGFR inhibitors, like dovitinib and ponatinib, with multiple kinase 
targets. Importantly, our cell line findings highlight the importance of intrinsic 
resistance to FGFR inhibition in endometrial cancer, such that additional assessment 
of biomarkers of sensitivity and resistance may be required before the clinical 
success of FGFR inhibition is observed in patients. 
To better approach the question as to whether FGFR2N550K is a true 
resistance mutation, we stably transfected the sensitive non-N550K-mutant 
(FGFR2C383R) endometrial cancer cell line JHUEM-2 with an FGFR2N550K expressing 
construct and compared its response to FGFR inhibition with that of other JHUEM-2 
lines similarly transfected with relevant controls. Strikingly, the presence of 
FGFR2N550K in JHUEM-2 cells conferred a ~5 fold increase in IC50 to PD173074 in 
this cell line, confirming our BaF3 screen results that FGFR2N550K is indeed a true 
resistance mutation. Although there was no increase in resistance to dovitinib in the 
FGFR2N550K transfected JHUEM-2 cells, we hypothesize this is due to a combination 
of low levels of FGFR2N550K combined with receptor heterodimerization and the fact 
that the N550K allele provides relatively less resistance to dovitinib. Specifically in 
the BaF3 assay N550K provides less resistance to dovitinib than PD173074 (~15x 
WT IC50 vs ~250x WT IC50) but we must be cognisant of the fact that BaF3 cells 
express no endogenous FGFR2 and so we are measuring the drug resistance 
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associated with homodimerization of the FGFR2N550K allele. In contrast, the JHUEM-
2 cell line expresses a high level of endogenous FGFR2C383R and there are relatively 
low expression levels of FGFR2N550K compared to endogenous FGFR2C383R (see 
Figure 7). In this case we presume that the relative small proportion of receptor 
dimers carrying FGFR2N550K  on a background of high FGFR2C383R expression is 
sufficient to provide resistance to PD173074 but not to dovitinib. In order to provide 
additional data that FGFR2N550K provides resistance to dovitinib but not ponatinib, 
additional in vitro kinase assays were performed. These showed that showed that 
while both inhibitors showed poor activity against the gatekeeper mutation, ponatinib 
showed greater activity than dovitinib against the N550H mutation. Taken together 
this confirms our BaF3 data that FGFR2N550K is indeed a true resistance mutation, 
however we must await the clinical data to see to what extent this is reflected in 
patients.  
 In conclusion, we have identified FGFR2 mutations, including the common 
N550K mutation capable of conferring resistance to dovitinib in BaF3 assays. These 
drug-resistant mutations increase receptor tyrosine kinase activity by disengaging 
the molecular brake or by stabilizing the hydrophobic spine of FGFR2. Introduction of 
the drug resistant FGFR2N550K allele into the FGFR2C383R JHUEM cell line resulted in 
a 6 fold increase in resistance to PD173074. With the evaluation of four additional 
FGFR2 mutant endometrial cancer cell lines and the finding that only 2/4 endometrial 
cancer cell lines with N550K mutations, and 1/3 cell lines with S252W mutations are 
sensitive to dovitinib and ponatinib, additional markers of drug sensitivity and/or 
resistance are required. We look forward to the ongoing dovitinib trial in endometrial 
cancer patients to see if patients with heterozygous or homozygous activating kinase 
domain mutations respond as well as those with mutations in other domains. If 
previous experience with other kinase inhibitors can be assumed to hold true for anti-
FGFR agents, future drug design should focus on inhibiting the active conformation 
of the FGFRs, as well as the development of second-generation inhibitors targeting 
the gatekeeper form of FGFR2.  
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Materials and Methods 
Cell Lines and Reagents 
 BaF3 cells were cultured as previously described (44). The BaF3 cells used in 
this study were obtained directly from ATCC and were passaged for fewer than 6 
months after their receipt and as such reauthentification was not performed. The 
JHUEM-2, MFE280 and MFE296 cell lines was purchased from the RIKEN Cell 
Bank (Tsukuba, Japan), the DSMZ (Berlin, Germany) and the European Collection of 
Cell Cultures (Salisbury) respectively. AN3CA, HEC1A, Ishikawa, and KLE were 
provided by Dr. Paul Goodfellow (Washington University, St. Louis, MO). EI, EJ and 
EN1078D were provided by Dr Gordon Mills (MD Anderson Cancer Center, Houston, 
TX). Recombinant murine IL3 and human FGF10 were purchased from R&D 
Systems (Minneapolis, MN). Dovitinib and ponatinib were purchased from Selleck 
Chemicals (Houston, TX) and PD173074 was purchased from EMD Chemicals 
(Gibbstown, NJ). Phospho-FGFR (P-FGFR) antibody was purchased from Cell 
Signaling Technology (Genesearch Pty Ltd, Arundel, Australia), total FGFR2 (T-
FGFR) antibody was purchased from Santa Cruz Biotechnology (Thermo Fisher 
Scientific Pty Ltd, Scoresby, Australia), α-tubulin antibody was purchased from 
Sigma-Aldrich (Castle Hill, NSW, Australia) and IRDye 800 and IRDye 680LT 
secondary antibodies were purchased from Rockland (Jomar Biosciences Pty Ltd, 
Kensington, Australia).  
BaF3 Screen for Dovitinib-Resistant FGFR2 Mutations 
 BaF3 cells were stably transduced with pEF1a.FGFR2b.IRES.neo,  
pEF1a.FGFR2b.S252W.IRES.neo, or pEF1a.FGFR2b.N550K.IRES.neo plasmid 
DNA using Amaxa nucleofection and selected for 14 days in 1200 µg/ml G418, as 
previously reported (48).  Stably selected cells were plated at a density of 1x105 and 
4x105 cells/well in six 96 well plates each in BaF3 growth media without IL3, 
supplemented with 1nM FGF10 and 5 µg/ml heparan sulphate. Dovitinib was added 
to duplicate plates of each cell density at 5, 10, or 15x the IC50 (100, 200, 300 nM, 
respectively for FGFR2b and S252W expressing cells, and 2000, 4000, 6000 nM, 
respectively, for N550K expressing cells).  Fresh FGF10 and heparan sulphate were 
added every 2-3 days.  Colonies that grew out were expanded in media with FGF10 
and heparan sulphate and genomic DNA extracted using the GenElute Mammalian 
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Genomic DNA Miniprep kit (Sigma-Aldrich, St. Louis, MO). Inserted human FGFR2b 
was amplified using overlapping primer pairs (5’-ATGCCCAGCCCCACATCCAG-3’ 
and 5’-GACTGGAAGCCGCCCATTGGTG-3’; 5’-CCCAAGGAGGCGGTCACCG-3’ 
and 5’- GGCATGGTCTCCCTGCTCAGTG-3’) and sequenced in two directions for 
mutations in the intracellular domain of FGFR2b (sequencing primers available upon 
request). Mutations were confirmed in an independent PCR. Amino acid 
substitutions are listed according to isoform 2 of human FGFR2 (FGFR2b) 
(NP_075259.4).  
Site-Directed Mutagenesis  
 Each putative dovitinib-resistant mutation was introduced into full-length 
FGFR2b by site-directed mutagenesis (SDM), as previously described (49).  Briefly, 
SDM was performed on 50 ng of pEF1a.FGFR2b.IRES.neo plasmid DNA using the 
QuikChange II XL Site-Directed Mutagenesis kit (Agilent Technologies, Santa Clara, 
CA).  SDM primers were designed to introduce the desired dovitinib-resistant 
mutation as well as a silent mutation to introduce a restriction site for ease in 
screening (primers available upon request).  Plasmid DNA was isolated using the 
Plasmid DNA Miniprep Kit (Qiagen, Valencia, CA) and diagnostic restriction digests 
performed.  Plasmid DNA was then isolated from SDM-positive clones using the 
Qiagen EndoFree Plasmid MaxiPrep kit (Qiagen, Valencia, CA).  Mutations were 
confirmed by sequencing of the entire coding region of FGFR2b (primers listed in 
Supplemental Table 3).  
Generation of BaF3 cells Stably Expressing Dovitinib-Resistant FGFR2b 
Mutations 
 pEF1a.FGFR2b.IRES.neo or the various FGFR2b mutant plasmids were 
introduced into BaF3 cells using the Amaxa nucleofector kit V, according to the 
manufacturer’s instructions (Amaxa, Walkersville, MD). Cells were selected in growth 
media containing 1200 µg/ml G418 and 5 ng/ml IL3 for 14 days and frozen down. 
Proliferation assays in the presence or absence of drug were performed in BaF3 
cells that had not been passaged for more than 5 weeks after this initial freeze.    
Generation of JHUEM-2 cells Stably Expressing Wild-type and Mutant FGFR2b 
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JHUEM-2 cells were infected with lentiviral particles containing 
pEF1α.FGFR2b.IRES.neo plasmids encoding wild-type FGFR2b, FGFR2bY376C or 
FGFR2bN550K. A JHUEM-2 line was also infected with an empty pEF1α.IRES.neo 
vector as a control. Cells were then selected in growth media containing 900 µg/mL 
G418 for 14 days and frozen down. 
IC50 Analysis 
 BaF3 cells expressing wild-type or mutant FGFR2b were plated at either 3000 
or 10,000 cells per well in 96 well plates in BaF3 media without IL3, supplemented 
with 1nM FGF10 and 5 µg/ml heparan sulphate.  Dovitinib and PD173074 were 
added at half-log dilutions ranging from 10 µM - 3 nM, while ponatinib was added at 
half-log dilutions ranging from 1 µM - 0.1 nM respectively. After 72 hours, cell 
viability was measured using the ViaLight kit (Lonza, Walkersville, MD). Values were 
normalized to DMSO vehicle control wells and IC50 values generated by nonlinear 
regression analysis with variable slope using Prism software version 4.0c (GraphPad 
Software, San Diego, CA). For the ponatinib experiments, 3000 cells per well were 
seeded and assayed in triplicate on two independent days. As biological replicate 
data for dovitinib and PD173074 had been generated with 10000 cells per well, 
these assays were repeated a third time with 3000 cells per well with no significant 
differences observed and the presented IC50 values are the replicates of these three 
independent experiments.  
Parental endometrial cancer cell lines and stably transfected JHUEM-2 cells 
were seeded at 3,000 cells per well in 96 well plates in their individual growth media. 
After 24 hours, dovitinib, PD173074 and ponatinib were added at half-log dilutions (1 
nM to 10 µM). Following 72 hours of drug treatment, cell viability was assessed 
using the CyQUANT Cell Proliferation Assay Kit (Life Technologies, Carlsbad, CA). 
Values were normalized to DMSO vehicle control wells and IC50 values calculated as 
described above. Proliferation assays were performed in triplicate on two 
independent days and the results averaged. 
Receptor Phosphorylation in Response to Ligand Treatment 
 BaF3 cells expressing wild-type or mutant FGFR2 were washed twice in 
media minus IL3. Cells were then resuspended in 200 µL of BaF3 media minus IL3 
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containing 5 µg/mL heparan sulphate and 16 nM FGF10 for 7.5 minutes. Cells were 
centrifuged at 1000 rpm for 5 minutes, the supernatant discarded and the cell pellet 
resuspended in 200 µL lysis buffer (1% Triton X-100, 50 mM Tris-HCl (pH 7.4), 150 
mM NaCl, 2 mM Na3VO4 and 10 mM NaF). The protein concentration was 
determined using a BioRad quick start kit. A total of 150 µg of protein was subjected 
to SDS-gel electrophoresis on a 4-12% bis-acrylamide gradient gel, transferred to a 
nitrocellulose membrane, blocked with odyssey blocking buffer and incubated with 
the primary antibody diluted in Odyssey blocking buffer overnight at 4°C. The 
membranes were washed with TBS-T and incubated with the secondary antibody 
diluted in Odyssey blocking buffer for 1 hour at room temperature. After another 
washing step the membrane was scanned using a Lycor flat bed scanner.  
Inhibition of Receptor Phosphorylation in Response to Ligand  
 BaF3 cells expressing wild-type or mutant FGFR2 were grown in T75 flasks in 
50 mL BaF3 media. Cells were washed twice with IL3-free media, resuspended in 35 
mL IL3-free media, and the cells evenly split into seven T25 flasks. An FGFR 
inhibitor was added to final concentrations of 1, 10, 30, 100, 300, 1000 nM or DMSO 
control corresponding to the highest FGFR inhibitor concentration (0.01% v/v). Cells 
were incubated with the inhibitors for 90 minutes at 37°C, pelleted at 1000 rpm, and 
the pellet was resuspended in BaF3 media minus IL3 containing 5 µg/mL heparan 
sulphate and 16 nM FGF10 for 7.5 minutes. After the incubation period, cells were 
centrifuged at 1000 rpm for 5 minutes, the supernatant discarded and the cells 
resuspended in 200 µL lysis buffer. The cell lysates were processed and subjected 
to SDS gel electrophoresis as described above. 
Structural Modeling 
 Binding of dovitinib to FGFR2 kinase was modeled by superimposing the 
structure of the A-loop phosphorylated activated wild-type FGFR2 kinase domain 
(PDB ID: 2PVF) (36) onto the structure of the CHK-1 kinase domain in complex with 
the inhibitor 4-(Aminoalkylamino)-3-benzimidazole-quinolinones complex structure 
(PDB ID: 2GDO) (37). Similarly, binding of ponatinib to FGFR2 kinase was modeled 
by superimposing the structure of the A-loop phosphorylated activated wild-type 
FGFR2 kinase domain (PDB ID: 2PVF) (36) onto the structure of the ABL kinase in 
complex with ponatinib (PDB ID: 3OY3) (50). Modeling of the pathogenic mutations 
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was performed and analyzed using O (51). Atomic superimpositions were performed 
using program lsqkab (52) in CCP4 Suite (53) and structural representations were 
prepared using PyMol (54). 
Protein Expression and Purification 
 The cDNA fragment encoding residues P459 to E769 of human FGFR2c 
(Accession code: NP_075259) was amplified by PCR and subcloned into pET 
bacterial expression vector with an NH2-terminal 6XHis-tag to aid in protein 
purification. Point mutations (M536I, M538I, I548V, N550H, N550K, N550S, V565I, 
E566G, L618M and K660E) were introduced using QuikChange site-directed 
mutagenesis kit (Stratagene). The bacterial strain BL21 (DE3) cells were 
transformed with the expression constructs, and kinase expression was induced with 
1 mM isopropyl-L-thio-B-D-galactopyranoside overnight at the appropriate 
temperature. The cells were lysed, and the soluble kinase proteins were purified 
according to the published protocol (36). N-terminally His-tagged substrate peptide 
consisting of residues L762 to T822 of FGFR2 was expressed and purified similar to 
the kinase domain.  The substrate peptide corresponds to the C-terminal tail of 
FGFR2 and contains five authentic tyrosine phosphorylation sites (Y770, Y780, 
Y784, Y806, Y813). 
 Kinase Assay  
 Wild-type and mutated FGFR2 kinases were mixed with reaction solutions 
containing ATP, MgCl2 and the substrate peptide. The final concentrations of the 
reaction mix are: kinase 0.5 mg/mL, substrate 2.17 mg/ml, ATP 10 mM and MgCl2 
20 mM. The reactions were quenched at different time points by adding 100 mM 
EDTA. The progress of the substrate phosphorylation was followed by native-PAGE, 
and tyrosine phosphorylation content of the substrate peptide was quantified by time-
resolved MALDI-TOF mass spectrometry using a Bruker Autoflex mass spectrometer 
operated in linear mode according to the published protocol by comparing signals 
from phosphorylated and the cognate non-phosphorylated peptides (55). 
In vitro Kinase Inhibition Assay 
Wild-type FGFR2 kinase and the N550H and V565I mutants were incubated for 5 
minutes with reaction solutions containing ATP, MgCl2 and increasing concentrations 
of either dovitinib or ponatinib. The final concentrations of kinase, ATP and MgCl2 
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were 90 µM, 5.33 mM, 10.66 mM, respectively. The molar ratios of kinase:inhibitor in 
the reaction mix were 1:0, 1:0.2, 1:0.5, 1:1, 1:2, 1:5 or 1:10. The reactions were 
quenched by adding EDTA to a final concentration of 69.6 mM, and the progress of 
the kinase autophosphorylation/inhibition was monitored by native-PAGE. 
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Figure Legends.  
Figure 1. Identified FGFR2 mutations confer dovitinib resistance in stable 
BaF3.FGFR2 cells. A, The ribbon diagram of the A-loop phosphorylated activated 
wild-type FGFR2 kinase structure (PDB ID: 2PVF) (36) showing the locations of the 
drug-resistant mutations. The A-loop and kinase hinge are colored light purple and 
light orange, respectively. The drug-resistant mutations are rendered as ball-and-
stick. The AMP-PCP (the ATP analog) is shown in both ball-and-stick representation 
and a semi-transparent surface. B, Western blot analysis of stable BaF3 cells 
expressing wild-type or mutant FGFR2 using an anti-FGFR2 antibody (BEK-C17) or 
anti-tubulin antibody as loading control. C, Stable BaF3-FGFR2 cells were seeded in 
96 well plates in media containing 5 µg/mL heparan sulphate and 1nM FGF10 and 
dovitinib was added in concentrations ranging from 3nM to 10µM. The cells were 
incubated at 37°C for 72 hours and proliferation was measured using the ViaLight 
proliferation kit and the IC50 was calculated using PrismGraphPad.  
 
Figure 2. The molecular mechanisms by which mutations confer resistance to 
dovitinib A-B, Gatekeeper V565I mutation confers resistance to dovitinib through 
steric hinderance.  Binding of dovitinib (in yellow, partial, taken from the CHK-1 and 
inhibitor 4-(Aminoalkylamino)-3-benzimidazole-quinolinones complex structure, PDB 
ID: 2GDO) (37) is modeled onto the A-loop phosphorylated activated wild-type 
FGFR2 kinase structure (PDB ID: 2PVF) (36).  Hydrogen bonds between the kinase 
and dovitinib are colored yellow. The molecular surface of dovitinib is shown to 
emphasize the steric clash with the mutated I565. C-F, Mutations at N550 and E566 
confer dovitinib-resistance by activating the kinase through disengagment of the 
molecular brake.  The molecular brake is engaged at the kinase hinge region in the 
unphosphorylated unactivated wild-type FGFR2 kinase (Panel C, PDB ID: 2PSQ) 
(36), and is disengaged by A-loop tyrosine phosphorylation (Panel D, PDB ID: 2PVF) 
(36), or by mutations at N550 (Panel E, PDB ID: 2PWL) (36) and E566 (Panel F, 
PDB ID: 2PY3) (36). G, Some mutations confer dovitinib resistance by activating the 
kinase through strengthening the hydrophobic spine of the FGFR2 kinase.  The 
hydrophobic spine is shown as semitransparent surface.  Residues comprising the 
hydrophobic spine are rendered as sticks.  The drug resistant mutations targeting 
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residues V565, M536, M538, I548, and L618 are colored and labeled green, and the 
others are labeled white. 
 
Figure 3. Dovitinib-resistant mutations increase the intrinsic kinase activity of 
FGFR2. A, The substrate phosphorylation activities of wild-type and mutated FGFR2 
kinase domain harboring the drug-resistant mutations were compared using native-
PAGE (panel I) coupled with time-resolved mass spectrometry (panels II and III).  
For accuracy only the early time points (30 and 60 sec) MS data, which are in the 
linear phase of the kinase assay, were processed. The percentage of at least one 
site phosphorylation on the substrate (panel III) was estimated using the peak 
intensity data generated by mass spectrometry. B, Stable BaF3.FGFR2 cells were 
seeded at 10000 cells/well in 96 well plates in media containing 5 µg/ml heparan 
sulphate and 1nM FGF10. The cells were incubated at 37°C for 72 hours and 
proliferation was measured using the ViaLight proliferation kit. Presented is the 
increase in proliferation compared to FGFR2 wild-type cells. C, Stable BaF3 cells 
expressing wild-type or mutant FGFR2 were stimulated for 7.5 minutes with media 
containing 5 µg/ml heparan sulphate and 16 nM FGF10. After the stimulation period 
the cells were lysed in lysis buffer containing phosphatase inhibitors and 150 µg of 
total protein were separated on a SDS-gel, transferred to a nitrocellulose membrane 
and probed with an anti pan-phospho FGFR-, anti-FGFR2 (BEK-C17) and anti-
tubulin antibodies. The ratio of phospho to total FGFR2 was calculated by 
densitometry using Odyssey 3.0 software. 
 
Figure 4. Dovitinib resistance mutations are similarly resistant to PD173074 
but are almost all sensitive to ponatinib. A, Stable BaF3-FGFR2 cells were 
seeded in 96 well plates in media containing 5 µg/mL heparan sulphate and 1nM 
FGF10 and PD173074 was added in concentrations ranging from 3 nM to 10 µM. 
The cells were incubated at 37°C for 72 hours and proliferation was measured using 
the ViaLight proliferation kit and the IC50 was calculated using Prism (GraphPad 
software, San Diego, CA). B, Cells were treated as in Figure 4A, but 0.1 nM - 1 µM 
of ponatinib was added to each stable cell line.  
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Figure 5. Change in FGFR2 phosphorylation in response to treatment with 
dovitinib and ponatinib. A, Stable BaF3.FGFR2 cells were pre-treated in IL3-free 
BaF3 media for 90 minutes at 37°C. After the 90 minutes incubation period the 
media was removed and the cells were incubated for 7.5 minutes at 37°C with media 
containing 5 µg/mL heparan sulphate and 16 nM FGF10. Cells were lysed in lysis 
buffer containing phosphatase inhibitors and 150 µg of total protein were separated 
on a SDS-gel, transferred to a nitrocellulose membrane and probed using an anti 
pan-phospho-, anti-FGFR2 (BEK-C17) and anti-tubulin antibodies. B, Densitometry 
analysis of the change in phosphorylation due to pre-treatment with dovitinib and 
ponatinib. The ratio of phospho to total FGFR2 was calculated by densitometry using 
Odyssey 3.0 software and the concentration required to decrease the 
phosphorylation to 50% as compared to wild-type.  
 
Figure 6. The V565I gatekeeper FGFR2 kinase mutant is also refractory to 
inhibition by ponatinib due to steric conflicts. Ponatinib taken from the Abl-
ponatinib complex structure (PDB ID: 3OY3) (50) was modeled onto the A-loop 
phosphorylated activated wild-type FGFR2 kinase structure (PDB ID: 2PVF) (36). 
The molecular surface of ponatinib (in yellow) is shown to emphasize the steric clash 
with the mutated I565.  
 
Figure 7. The N550K mutation confers resistance to PD173074, but not 
dovitinib or ponatinib, when expressed in FGFR inhibitor sensitive JHUEM-2 
cells. A, Stably transfected JHUEM-2 cells were seeded in 96 well plates 24 hours 
prior to drug addition. Dovitinib, PD173074 and ponatinib were added in increasing 
concentrations from 1 nM to 10 µM. The cells were incubated at 37°C for 72 hours 
and proliferation was measured using the CyQUANT Cell Proliferation Assay kit and 
the IC50 was calculated. B, Western blots demonstrating FGFR2 expression levels in 
stably transfected JHUEM-2 lines. EV, empty vector; WT, wild-type. C. Both dovitinib 
and ponatinib are potent inhibitors of the wild-type FGFR2 kinase whereas only 
ponatinib effectively inhibits the N550H mutant FGFR2.  Due to the steric clash, 
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neither dovitinib nor ponatinib is capable of inhibiting the V565I “gatekeeper” mutant. 
The control lane 1 shows extent of phosphorylation in the absence of inhibitors.  In 
lanes 2 to 7, increasing concentrations of inhibitors were added into the 
autophosphorylation reactions to inhibit the kinase autophosphorylation.  The 
kinase:inhibitor molar ratios of lane 2 to 7 are 1:0.2, 1:0.5, 1:1, 1:2, 1:5 and 1:10 
respectively. The control lane 0 is the kinase in the absence of ATP: MgCl2.  
 
Supplemental Figure 1. Sensitivity of compound FGFR2S252W dovitinib 
resistance mutations to dovitinib. Presented is the IC50’s of FGFR2 wild-type, 
FGFR2S252W wild-type and FGFR2S252W mutant (N550T, E566A and K642N) BaF3 
lines. All three kinase mutations identified conferred significant resistance to 
dovitinib. 
 
Supplemental Figure 2. Dovitinib-resistant mutations increase the intrinsic 
kinase activity of FGFR2. The substrate phosphorylation activities of wild-type and 
mutated FGFR2 kinase domain harboring the drug-resistant mutations were 
compared using native-PAGE (panel I) coupled with time-resolved mass 
spectrometry (panels II and III). For accuracy only the early time point (30 and 60 
sec) MS data, which are in the linear phase of the kinase assay, were processed. 
The percentage of at-least one site phosphorylation on the substrate (panel III) was 
estimated by comparing peak intensities generated by mass spectrometry of 
phosphorylated and nonphosphorylated substrate peptides. 
 
Supplemental Figure 3. Ligand independent proliferation of stable BAF3-
FGFR2 cells. A, FGFR2 wild-type and mutants are not sufficient to drive ligand 
independent proliferation in BaF3 cells.  Stable BaF3.FGFR2 cells were seeded at 
10000 cells/well in 96 well plates in IL3-free media. The cells were incubated at 37°C 
for 72 hours and proliferation was measured using the ViaLight proliferation kit. 
Presented is the increase in proliferation compared to FGFR2 wild-type cells. B, In 
both the absence and presence of ligand, the homologous N546K mutation in 
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FGFR1c can drive significantly more BaF3 proliferation than the FGFR2c N549K 
mutation, indicating the relative weak strength of FGFR2 in vivo.   
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Table 1.  
Endometrial 
Cancer Cell 
Line 
FGFR2 status 
Dovitinib IC50 
(nM) 
PD173074 IC50 
(nM) 
Ponatinib IC50 
(nM) 
AN3CA FGFR2N550K 449 ± 114 761 ± 130 58 ± 13 
MFE296 FGFR2N550K 614 ± 18 821 ± 71 104 ± 29 
EJ FGFR2N550K 2374 ± 789 >10,000 949 ± 241 
EN1078D FGFR2N550K 770 ± 174 4475 ± 258 614 ± 18 
MFE280 FGFR2S252W 1503 ± 381 821 ± 71 230 ± 52 
EI FGFR2S252W 1268 ± 146 5161 ± 149 729 ± 21 
JHUEM-2 FGFR2C383R 558 ± 111 183 ± 41 145 ± 33 
HEC1A Wild-type 3572 ± 409 >10,000 1519 ± 260 
Ishikawa Wild-type 1850 ± 662 8749 ± 1251 669 ± 222 
KLE Wild-type 4751 ± 1933 >10,000 1167 ± 167 
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Supplemental Table 1. Number of colonies obtained in the BaF3 screen 
 
 
Cells 
seeded Wells Wells with Clones
Mutant 
clones of Frequency Frequency
per well seeded outgrowth sequenced
sequenced 
colonies among clones among mutants
parental 28 80
M538I 1 2.9 14.3
N550H 4 11.4 57.1
E566G 1 2.9 14.3
L618M 1 2.9 14.3
parental 6 31.6
M536I 1 5.3 7.7
I548V 1 5.3 7.7
N550H 10 52.6 76.9
V565I 1 5.3 7.7
parental 3 33.3
N550H 3 33.3 50
N550K 1 11.1 16.7
N550S 1 11.1 16.7
Y770IfsX14 1 11.1 16.7
parental 17 85
N550T 1 5 33.3
E566A 2 10 66.7
parental 14 93.3
K642N 1 6.7 100
Mutants Occurrence
100 nM 
(5xIC50)
1x10^5 192 31 24
7 of 35
4x10^5 42 11
200 nM 
(10XIC50)
1x10^5 192 8 8
13 of 19
4x10^5 192 11 11
6 of 9
4x10^5 192 6 6
1x10^5 192 3 3
Screen
FGFR2b 
S252W 
screen
100 nM 
(5xIC50)
1x10^5 192
200 nM 
(10XIC50)
1x10^5 192
FGFR2b 
screen
300 nM 
(15xIC50)
192
Concentration
none
4x10^5 192 147
148
20
3 of 20
4x10^5 192 58 0
29
1 of 15
4x10^5 192 18 14
300 nM 
(15xIC50)
1x10^5 192 4 1
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